小結(jié)噻嗎洛爾是一種有效、安全、價廉的藥物，在皮膚科的應(yīng)用主要體現(xiàn)在血管性病變和促進創(chuàng)面愈合方面，臨床應(yīng)用前景廣闊。目前國內(nèi)唯一上市銷售的外用劑型僅為滴眼液，但使用方法繁瑣，不易控制劑量，會降低患者依從性，亟需開發(fā)更合適的劑型。噻嗎洛爾的具體作用機制亦尚未得到充分研究，最佳的藥物濃度、給藥次數(shù)、用藥時間也仍未確定，未來應(yīng)對這些方面進行更多大樣本量的RCT研究。參考文獻：[1]俞好央，路濤.外用噻嗎洛爾在皮膚科的臨床應(yīng)用進展[J].皮膚性病診療學(xué)雜志，2021，28（5）：420-424.[2]陳彬，仇雅璟，林曉曦.嬰幼兒血管瘤外用藥物治療研究進展[J].中華整形外科雜志，2019，35(5) : 502-506． [3]ROTTE RA，DE OLIVEI RAZNP.Infantile hemangio-ma:pathogenesis and mechanisms of action of propranolol[J] J Deutsch Dermatol Ges，2017，15 (12) : 1185-1190．[4]BOOS MD，CASTELO-SOCCIO L.Experience with topi- cal timolol maleate for the treatment of ulcerated infantile hemangiomas (IH)[J]．J Am Acad Dermatol，2016，74. [5]CHEN Q Y，CHANG L，QIU Y J，et al．Comparison of the efficacy between topical timolol and pulsed dye laser in the treatment of ulcerated infantile haemangiomas: a randomized controlled study[J].J Eur Acad Dermatol Venereol，2021，35(4) : e303-e305.[6]DANY M.Beta-blockers for pyogenic granuloma: a sys-tematic review of case reports，case series，and clinical trials[J].J Drugs Dermatol，2019，18 (10) : 1006-1010． [7]EL-TAWEEL A E A I，AL-ＲEFAIE A A A S A，SALEM K H A，et al.Topical β-blockers for pyogenic granulo- mas: a promising option for younger patients[J].J Cos- met Dermatol，2021，20(6) : 1801-1806． [8]張恒坡，曹冰青，尹光文等．馬來酸噻嗎洛爾滴眼液聯(lián)合冷凍治療化膿性肉芽腫臨床觀察[J].中國中西醫(yī)結(jié)合皮膚性病學(xué)雜志2017，16(5) : 436-437． [9]趙萬潤，曹蘭，潭龍鳳等．馬來酸噻嗎洛爾滴眼液聯(lián)合二氧化碳激光治療化膿性肉芽腫的療效觀察[J]．皮膚病與性病，2019，41(2) : 216-218． [10]CUBIＲX，PLANAS-CIUDAD S，GAＲCIA-MUＲET M P，et al.Topical timolol for paronychia and pseudopyo- genic granuloma in patients treatedwith epidermal growth factor receptor inhibitors and capecitabine[J]． JAMA Dermatology，2018，154(1) : 99-100. [11]SOLLENA P，MANNINO M，TASSONE F，et al.Efficacy of topical beta-blockers in the management of EGFR-in- hibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature[J]． Drugs Context，2019，8: 212613．[12]SIVAMANI Ｒ K，LAM S T，ISSEＲOFF Ｒ R.Beta adren-ergic receptors in keratinocytes[J].Dermatol Clin， 2007，25(4) : 643-653． [13]PULLAＲ C E，LE PＲOVOST G S，O’LEAＲY A P，et al.β2AＲ antagonists and β2AＲ gene deletion both pro-mote skin wound repair processes[J].J Invest Dermatol， 2012，132(8) : 2076-2084． [14]FU X.Wound healing center establishment and new tech-nology application in improving the wound healing quality in China[J].Burn Trauma，2020，8: tkaa038．[15]LI Y F，CHEN X Y，LEI T C.Inhibitory effect of timolol on topical glucocorticoid-induced skin telangiectasia[J].Mol Med Ｒep，2018，18(3) : 2823 -2831． [16]AL MOKADEM S M，IBＲAHIM A S M，EL SAYED A M.Efficacy of topical timolol 0.5% in the treatment of acne and rosacea: a multicentric study[J].J Clin Aesthet Dermatol，2020，13(3) : 22-27． [17]PAWAＲ M.Topical timolol in chronic，recalcitrant fis- sures and erosions of hand eczema[J].J Am Acad Der-matol，2021，84(3) : e125-e126． [18]ZHANG B，ZHANG N，WEI L，et al．Topical timolol maleate for treatment of tufted angioma[J].J Dermatol， 2019，46(11) : e402-e403． [19]PYLE T M，HEYMANN W Ｒ．Managing red scrotum syndrome(RSS)with topical timolol[J]．Int J Dermatol， 2019，58(8) : e162-e163．
